Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. (RGLS) Healthcare & Pipeline Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, pioneers microRNA-targeted therapies for diseases like Alport syndrome and autosomal dominant polycystic kidney disease. With a focus on target organ-selective delivery, Regulus operates in the competitive biotechnology sector, striving to advance its clinical pipeline and preclinical drug products.

What Is the Investment Thesis for RGLS?

Regulus Therapeutics Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on microRNA-targeted therapies offers a novel approach to treating diseases with significant unmet medical needs. Key value drivers include the successful completion of clinical trials for RG-012 in Alport syndrome and RGLS8429 in ADPKD. Positive clinical data could lead to significant stock appreciation. The company's market capitalization is $0.56 billion. Growth catalysts include potential partnerships or licensing agreements for its drug candidates. However, the company's negative profit margin of -10731.5% and gross margin of -77.1% highlight the financial risks associated with investing in a clinical-stage biopharmaceutical company. The company's beta is 0.37.

Based on FMP financials and quantitative analysis

RGLS Key Highlights

• Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on microRNA-targeted therapies.
• The company's lead product candidate, RG-012, is in Phase II clinical trial for Alport syndrome.
• RGLS8429, another key asset, is in Phase 1b clinical study for autosomal dominant polycystic kidney disease.
• Regulus is developing a pipeline of preclinical drug products with target organ-selective delivery strategies.
• The company's market capitalization is $0.56 billion.

Who Are RGLS's Competitors?

RGLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RGLS's Key Strengths?

• Novel microRNA-targeted therapy platform.
• Clinical-stage drug candidates with promising results.
• Strong intellectual property portfolio.
• Experienced management team.

What Are RGLS's Weaknesses?

• High cash burn rate.
• Reliance on clinical trial outcomes.
• Limited commercialization experience.
• Negative profit and gross margins.

What Could Drive RGLS Stock Higher?

• Phase II clinical trial results for RG-012 in Alport syndrome.
• Phase 1b clinical study results for RGLS8429 in ADPKD.
• Announcement of new strategic partnerships or licensing agreements.
• Continued development of preclinical drug products.

What Are the Key Risks for RGLS?

• Negative return on equity (-30.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Delays in regulatory approval process.
• Competition from other biotechnology companies.
• High cash burn rate and need for additional financing.
• Patent challenges to Regulus's intellectual property.

What Are the Growth Opportunities for RGLS?

• Advancement of RG-012 for Alport Syndrome: RG-012, currently in Phase II clinical trials, represents a significant growth opportunity for Regulus. Alport syndrome is a rare, life-threatening kidney disease with limited treatment options. Successful completion of Phase II and subsequent Phase III trials, followed by regulatory approval, could lead to substantial revenue generation. The market for Alport syndrome treatments is estimated to grow as awareness and diagnostic capabilities improve. Regulus's competitive advantage lies in its targeted approach to modulating miR-21, a key driver of Alport syndrome progression.
• Development of RGLS8429 for ADPKD: RGLS8429, an anti-miR targeting miR-17, is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a common genetic disorder characterized by the growth of cysts in the kidneys, leading to kidney failure. The ADPKD market is substantial, with a significant unmet need for effective therapies. Positive results from the Phase 1b study could pave the way for further clinical development and potential commercialization. Regulus's targeted approach to modulating miR-17 offers a potential advantage over existing treatments.
• Expansion of Preclinical Pipeline: Regulus is actively developing a pipeline of preclinical drug products, focusing on target organ-selective delivery strategies. This represents a significant growth opportunity, as successful development and commercialization of these products could diversify the company's revenue streams and reduce its reliance on RG-012 and RGLS8429. The company's expertise in miRNA-targeted therapies and target organ-selective delivery provides a competitive advantage in this area. The specific therapeutic areas targeted by these preclinical programs will determine the market size and potential revenue opportunities.
• Strategic Partnerships and Licensing Agreements: Regulus could pursue strategic partnerships or licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This could provide access to additional funding, expertise, and resources, as well as expand the company's reach into new markets. The terms of these agreements would vary depending on the specific assets and partners involved, but could include upfront payments, milestone payments, and royalties on future sales. Successful partnerships could significantly enhance Regulus's growth prospects.
• Expansion into New Therapeutic Areas: Regulus's miRNA-targeted therapy platform has the potential to be applied to a wide range of diseases beyond Alport syndrome and ADPKD. The company could expand its research and development efforts into new therapeutic areas, such as oncology, immunology, and neurology, to capitalize on this potential. This would require significant investment in research and development, but could also lead to substantial long-term growth. The market size and potential revenue opportunities would vary depending on the specific therapeutic areas targeted.

What Opportunities Does RGLS Have?

• Expansion into new therapeutic areas.
• Strategic partnerships with larger pharmaceutical companies.
• Positive clinical trial results leading to regulatory approval.
• Growing market for microRNA-targeted therapies.

What Threats Does RGLS Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other biotechnology companies.
• Patent challenges.

What Are RGLS's Competitive Advantages?

• Proprietary microRNA-targeted therapy platform.
• Strong intellectual property protection for its drug candidates.
• Expertise in target organ-selective delivery strategies.
• First-mover advantage in the field of microRNA-targeted therapeutics.

What Does RGLS Do?

Regulus Therapeutics Inc., founded in 2007 and headquartered in San Diego, California, is a biopharmaceutical company dedicated to discovering and developing innovative drugs that target microRNAs (miRNAs). These small non-coding RNA molecules play a crucial role in gene expression and are implicated in various diseases. Regulus's approach involves designing anti-miRs, which are molecules that bind to specific miRNAs and inhibit their activity, thereby modulating the expression of target genes and potentially treating diseases. The company's lead product candidate is RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for the treatment of Alport syndrome, a life-threatening genetic kidney disease. Another key asset is RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Beyond these clinical-stage programs, Regulus is actively developing a pipeline of preclinical drug products, emphasizing target organ-selective delivery strategies to enhance efficacy and minimize off-target effects. The company's research and development efforts are focused on addressing unmet medical needs in areas such as renal diseases and other therapeutic areas where miRNA modulation holds promise. With a team of 34 employees, Regulus is committed to advancing its miRNA-targeted therapies through clinical development and ultimately bringing new treatment options to patients.

What Products and Services Does RGLS Offer?

• Discovers and develops drugs targeting microRNAs.
• Focuses on treating diseases with significant unmet medical needs.
• Develops anti-miR molecules to inhibit specific microRNAs.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Utilizes target organ-selective delivery strategies to enhance drug efficacy.
• Develops a pipeline of preclinical drug products.

How Does RGLS Make Money?

• Develops and patents novel microRNA-targeted therapies.
• Conducts preclinical and clinical research to advance drug candidates.
• Seeks regulatory approval for its drug candidates.
• May out-license or partner with other pharmaceutical companies for commercialization.

What Industry Does RGLS Operate In?

Regulus Therapeutics Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The company's focus on microRNA-targeted therapies places it in a niche area of drug development, with potential advantages in addressing diseases with complex genetic underpinnings. The biotechnology industry is experiencing growth, driven by advances in genomics, proteomics, and personalized medicine. However, the industry is also facing challenges, including rising research and development costs, increasing regulatory scrutiny, and pricing pressures. Regulus competes with other biotechnology companies developing novel therapies for various diseases.

Who Are RGLS's Key Customers?

• Patients suffering from Alport syndrome.
• Patients suffering from autosomal dominant polycystic kidney disease.
• Potential pharmaceutical partners interested in licensing or acquiring Regulus's drug candidates.

Company Profile

Regulus Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Joseph P. Hagan. RGLS has traded publicly since 2012.

Regulus Therapeutics Inc. Financial Trajectory

Regulus Therapeutics Inc. (RGLS) reported $0 in revenue for Q1 2025, a decline of 100.0% compared to the prior quarter. The company recorded a net loss of $9.6M, with diluted EPS of $-0.15. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, RGLS averaged $-0.18 in diluted EPS.

How Regulus Therapeutics Inc. Is Valued

Regulus Therapeutics Inc. carries a market capitalization of $564.95M, placing it in the small-cap category.

ROE -31%Key Financial Metrics

Return on equity for Regulus Therapeutics Inc. stands at -30.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 16.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Regulus Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 46.81 places it in the safe zone, indicating low near-term bankruptcy risk.

3/8 beatsEarnings Track Record

Regulus Therapeutics Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.7% below estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Regulus Therapeutics Inc. revenue of about $44.2M for fiscal 2026, with EPS near $-1.06. The estimate reflects 5 contributing analysts.

Net sellingInsider Activity

The most recent 12 insider filings for Regulus Therapeutics Inc. break down as 12 sales and 0 purchases. On net that is roughly 302K shares disposed (about $368K), a signal worth weighing alongside the fundamentals.

RGLS Financials

RGLS Latest News

No recent news available for RGLS.

RGLS Analyst Consensus

RGLS MoonshotScore

Common Questions About RGLS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources